Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Next Previous
Trial Profile

An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deutetrabenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RIM-TD
  • Sponsors Auspex Pharmaceuticals

Most Recent Events

  • 23 Sep 2024 According to a Teva Pharmaceuticals media release, data were presented at the European College of Neuropsychopharmacology Congress (ECNP) in Milan 21-24 September 2024.
  • 23 Sep 2024 Results of new analysis from the European cohort of the RIM-TD open-label extension (OLE) study presented in a Teva Pharmaceuticals media release.
  • 10 Jun 2022 Results of a post hoc analysis of OLE study assessed long-term efficacy and safety of DTBZ in postmenopausal women presented at the 175th Annual Meeting of the American Psychiatric Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top